PulseAugur
EN
LIVE 21:16:12
中文(ZH) 葵花药业：盐酸氨溴索口服溶液申请注册上市许可获受理

Kweihua Pharmaceutical's Ambroxol Oral Solution Application Accepted

By PulseAugur Editorial · [1 sources] ·

Kweihua Pharmaceutical's subsidiary has received acceptance for its application to market Ambroxol Hydrochloride Oral Solution. The drug is intended for conditions involving viscous sputum and difficulty expectorating, such as acute and chronic bronchitis. This marks a step forward in the company's drug development pipeline. AI

RANK_REASON This is a product approval application acceptance, not a full release or significant market event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Kweihua Pharmaceutical's Ambroxol Oral Solution Application Accepted

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
This is a product approval application acceptance, not a full release or significant market event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
114 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Sunflower Pharmaceutical: Application for Marketing Authorization of Ambroxol Hydrochloride Oral Solution Accepted

    36氪获悉，葵花药业公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家药品监督管理局下发的关于盐酸氨溴索口服溶液申请注册上市许可的《受理通知书》。该药品拟定适应症（或功能主治）：用于急、慢性支气管炎引起的痰液粘稠、咳痰困难。

RELATED TOPICS